CD19 and acquired idiopathic inflammatory myopathy: In this regard, Schett and colleagues have evaluated CD19 CAR T‐cell therapy in eight patients with systemic lupus erythematosus (SLE), three with idiopathic inflammatory myositis (IIM), and four with systemic sclerosis (SSc) (Figure 1).